Liraglutide enhances myotube differentiation and muscle contractile activity upon electric pulse stimulation in mouse skeletal muscle cells.
Biosci Biotechnol Biochem · 2025
Last updated 2026-05-28In a lab study using mouse muscle cells, researchers tested the effects of a GLP-1 drug called liraglutide over three days. A moderate dose (0.5 micromolar) increased muscle cell growth and improved muscle function, while a much higher dose (10 micromolar) had the opposite effect, shrinking the cells.
AI summary of the abstract below.
| Journal | Biosci Biotechnol Biochem, 2025 |
|---|---|
| Citations | 4 |
| Molecules | liraglutide |
Abstract
Glucagon-like peptide-1 (GLP-1) is a potent incretin hormone produced by L-cells in the ileum and colon. Skeletal muscle, the most important organ for glucose metabolism, is also affected by GLP-1. Short-term administration of liraglutide, a GLP-1 analog, ameliorated glucose uptake in palmitate-treated type II diabetes models; however, the influence of long-term liraglutide administration on normal muscle cells has not been evaluated. We analyzed the effects of chronic (3 consecutive days) administration of liraglutide at various concentrations on healthy C2C12 skeletal muscle cells by investigating morphological changes, muscle contractile properties, and glucose uptake. Liraglutide administration at an appropriate dose (0.5 μm) had positive effects, including the promotion of muscle hypertrophy, in C2C12 cells; however, excessive administration (10 μm) had atrophic effects. Therefore, proper liraglutide dosing is very important.
Verbatim abstract via PubMed 40258338 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.